EMEA-001637-PIP01-13
Key facts
| Active substance |
Human normal immunoglobulin
|
| Therapeutic area |
Immunology-Rheumatology-Transplantation
|
| Decision number |
P/0047/2014
|
| PIP number |
EMEA-001637-PIP01-13
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of Primary Immunodeficiency (PID)
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Baxter Innovations GmbH
Austria |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|
| Compliance procedure number |
EMEA-001637-PIP01-13
|
| Compliance opinion date |
16/01/2015
|
| Compliance outcome |
positive
|